3X6 Stock Chart & Stats
€13.80
-€0.20(-1.43%)
At close: 4:00 PM EDT
€13.80
-€0.20(-1.43%)
Day’s Range― - ―
52-Week Range€12.30 - €29.60
Previous CloseN/A
Volume153.00
Average Volume (3M)0.00
Market Cap
€460.74M
Enterprise Value€637.45M
Total Cash (Recent Filing)€40.96M
Total Debt (Recent Filing)€26.91M
Price to Earnings (P/E)24.9
Beta0.62
Next Earnings
Sep 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.63
Shares Outstanding34,237,150
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)3.07
Price to Sales (P/S)5.04
P/FCF Ratio17.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€30.39Price Target Upside120.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)€2.62M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsGross margins above 85% indicate durable software economics and strong pricing power in healthcare IT. High margins support reinvestment in product development, absorb incremental sales costs for land-and-expand motions, and provide a stable profit buffer versus cyclical revenue swings over months.
Conservative Balance SheetA debt-to-equity of 0.09 shows low financial leverage and high balance sheet flexibility. That conservatism supports investment, M&A optionality, and resilience through provider budget cycles, reducing refinancing and solvency risk across a 2-6 month horizon and longer.
Recurring, Sticky Revenue ModelReliance on subscription and recurring fees plus long hospital switching cycles creates predictable cash flows and strong customer retention. Land-and-expand dynamics enable contracted ARPU growth within accounts, making revenue streams durable and visibility higher over multi-month periods.
Bears Say
Declining Free Cash Flow GrowthA 13.4% decline in free cash flow growth signals weaker cash conversion versus prior periods. If the trend persists it can restrict discretionary investment, reduce ability to fund share returns or acquisitions, and pressure the company’s financial flexibility over the medium term.
Modest Net Profitability / Low ROEModerate net margins and low ROE suggest earnings conversion and capital efficiency lag peers. This limits internal funding for growth and reduces incremental returns on shareholder capital, making it harder to scale profitability even if top-line grows modestly over coming quarters.
Customer / Market ConcentrationConcentration in the US hospital market exposes revenue to domestic reimbursement, regulatory shifts, and provider budget cycles. Geographic and end-market concentration raises structural sensitivity to policy or spending changes that could constrain growth or renewals over several months.
Craneware News
3X6 FAQ
What was Craneware Plc’s price range in the past 12 months?
Craneware Plc lowest stock price was €12.30 and its highest was €29.60 in the past 12 months.
What is Craneware Plc’s market cap?
Craneware Plc’s market cap is €460.74M.
When is Craneware Plc’s upcoming earnings report date?
Craneware Plc’s upcoming earnings report date is Sep 22, 2026 which is in 49 days.
How were Craneware Plc’s earnings last quarter?
Craneware Plc released its earnings results on Mar 02, 2026. The company reported €0.499 earnings per share for the quarter, beating the consensus estimate of N/A by €0.499.
Is Craneware Plc overvalued?
According to Wall Street analysts Craneware Plc’s price is currently Undervalued.
Does Craneware Plc pay dividends?
Craneware Plc does not currently pay dividends.
What is Craneware Plc’s EPS estimate?
Craneware Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Craneware Plc have?
Craneware Plc has 34,237,150 shares outstanding.
What happened to Craneware Plc’s price movement after its last earnings report?
Craneware Plc reported an EPS of €0.499 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.599%.
Which hedge fund is a major shareholder of Craneware Plc?
Currently, no hedge funds are holding shares in DE:3X6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Craneware Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€30.39 (120.18% Upside)
€30.39 (120.18% Upside)
Insider Transactions
Bought Shares
Worth £107.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.04%
12-Months-Change
Fundamentals
Return on Equity
2.82%
Trailing 12-Months
Asset Growth
-13.53%
Trailing 12-Months
Company Description
Craneware Plc
Craneware plc, with its associated entities, is dedicated to creating, distributing, and maintaining cutting-edge software applications tailored for the U.S. healthcare industry. Its extensive suite of products is designed to streamline and improve a wide array of operational functions for healthcare organizations. Among its flagship offerings is the Chargemaster Toolkit, an automated, cloud-hosted platform for charge master administration, crucial for enabling providers to achieve optimal and legitimate revenue reimbursement. Trisus Supply facilitates the identification and resolution of data inconsistencies between disparate systems. The Physician Revenue Toolkit, a Software-as-a-Service (SaaS) solution, empowers the oversight of physician group performance indicators, billing rates, procedural codes, relative value units, and fee schedules. Complementing these are Reference Plus, another SaaS tool for comprehensive chargemaster analytics, and Pharmacy ChargeLink, engineered to bolster charge capture, pricing strategies, and cost control within pharmacy operations. Furthermore, the company offers integration software that autonomously uploads chargemaster modifications to patient billing systems, thereby ensuring billing precision. The Trisus Pricing Analyzer, a SaaS application, streamlines the pricing model development process. Extending its capabilities, Craneware delivers tools for regulatory adherence and financial oversight: InSight Medical Necessity, a SaaS solution for validating the medical necessity required by U.S. payers and for creating advance beneficiary notices; Trisus Claims Informatics, a program that automates the review of claims and coding; and InSight Audit, a browser-based audit management application for healthcare entities to handle governmental and commercial examinations. Additionally, the firm presents Trisus Healthcare Intelligence, a platform for cost analysis and resource optimization; solutions for pricing transparency; and InSight Denials, which facilitates the analysis, tracking, trending, and reporting of denial data, further supported by appeals management services. Beyond its software offerings, Craneware provides comprehensive client success management, specialized consulting, and an array of professional services. The organization also oversees its own sales, marketing efforts, and continuous product and software innovation. Founded in 1999, Craneware plc has its corporate headquarters situated in Edinburgh, United Kingdom.
3X6 Stock 12 Month Forecast
Average Price Target
€30.39
▲(120.18% Upside)








